The MoU signed in 2022 has progressed and culminated in the subsumption of FOGSI-led Manyata initiative’s 20 quality standards across NABH’s Certification programs
The program aims to accelerate the development of 6 Indian innovations to improve ease of access to diagnostics and treatment monitoring
He has 35+ years of experience in understanding of business and products, analytical ability, eye for detail and computer literacy and knowledge of recent trends.
The INTerpath-009 clinical trial demonstrates continued expansion of the INTerpath clinical program
JB’s absolute Scope1 & Scope2 emissions reduced by 13.9 % in the last financial year, despite turnover increasing by 11%
Efficacy and safety from this phase IV study were consistent with data from the Vabysmo phase III DME studies
VYALEV is the first and only subcutaneous 24-hour continuous infusion of levodopa-based therapy for the treatment of motor fluctuations in advanced Parkinson's disease
India has been declared ‘functional’ against all the core regulatory functions of the WHO Global Benchmarking Tool Version VI
The partnership marks a pivotal step towards developing new therapies for combating Sickle Cell Disease
WHO estimates suggest that 150 million people worldwide are affected by Trachoma
Subscribe To Our Newsletter & Stay Updated
